Pure Indulgence Aesthetics, a medical spa, was cited for buying Botox from unauthorized sources and lacking product identifiers.
What happened
FDA inspected Pure Indulgence Aesthetics on December 2nd, 3rd, and 12th, 2025. Comparing Botox purchase records from AbbVie with patient treatment records, FDA found the firm dispensed significantly more Botox units than it purchased, and the firm did not explain the discrepancy. FDA also found an unlabeled clear vial in the facility’s trash that laboratory analysis confirmed contained botulinum neurotoxin type A; it lacked a product identifier.
What FDA found
Pure Indulgence could not show that it bought Botox only from authorized trading partners (businesses allowed in the drug supply chain), because purchase records did not match the amount administered to patients.
FD&C Act Section 582(d)(3)Pure Indulgence had an unlabeled vial of botulinum neurotoxin type A and could not provide a label or packaging with the required product identifier (standardized label with lot and expiration).
FD&C Act Section 582(d)(2)
What FDA wants
Within 15 working days of receipt, notify FDA in writing of the specific steps taken to correct the violations, include documentation and an explanation of how recurrence will be prevented, and state any reason and timeline for delay.
Who should pay attention
- medical spas and clinics that administer Botox
- dispensers that buy prescription drugs from secondary suppliers
- quality teams verifying DSCSA trading partner and product identifier compliance
This is a summary. Read the original letter on fda.gov.